Background. Pain is a common and dose-limiting side effect of many potentially curative cancer chemotherapeutic agents. This chemotherapy-induced pain (CIP) affects the quality of life of cancer patients and survivors and hampers the optimal clinical management of chemotherapy in cancer patients. The underlying mechanisms remain largely unknown, but changes in levels of cytokines/chemokines may contribute to the pathophysiology of CIP.
Introduction
Most cancer patients receiving chemotherapy are unable to complete full or optimal treatment schedules because many potentially curative cancer chemotherapeutic agents cause pain. This pathological pain may be short lasting (not more than seven days) and occur immediately within one to three days after administration of paclitaxel, a firstline chemotherapeutic agent used for the treatment of many types of cancers, or persist for weeks to years after cessation of chemotherapy (for a review, see [1] ). The chemotherapy-induced chronic (neuropathic) pain (CINP) is extremely debilitating and severely affects the quality of life of 10% to 100% of cancer patients and survivors depending upon the particular anticancer drug(s) used, the dosing regimen, treatment duration, and preexisting neuropathy of other origin, such as diabetes [2] . It usually presents as an impairment in sensory function that develops initially in the feet and hands in a "stocking and glove" distribution, respectively, due to the vulnerability of the long nerves [3] . CINP may lead to dose reduction of the cancer chemotherapy agents, a switch to less efficacious agents, or even discontinuation of treatment [2] . CINP is resistant to most of currently available drugs (all of which either have limited efficacy and/or have adverse side effects). Indeed, most of the anticonvulsants and tricyclic antidepressants that are typically used for treatment of other types of neuropathic pain have little or no effect on CIPN, but there is some clinical evidence of efficacy for duloxetine, a neuronal serotonin and norepinephrine reuptake inhibitor (see, e.g., [4] ).
Despite its clinical relevance, the underlying mechanisms of CINP are poorly understood. Therefore, there is a pressing need to understand the pathophysiological processes that underlie persistent pain in this incapacitating condition to devise novel therapeutic strategies. Cytokines, small intracellular regulatory proteins secreted by immune and other cells in the periphery and neurons and glia in the central nervous system [5] , have been implicated in the pathophysiology of other types of peripheral neuropathic pain (NP), such as nerve injuryinduced NP. Indeed, there is evidence that certain proinflammatory cytokines are involved in the initiation and persistence of pain hypersensitivity caused by inflammation or nerve injury. For example, interferon-gamma (IFN-c) has been shown to induce hyperexcitability of spinal dorsal horn neurons in vitro, indicating its potential involvement in central mechanisms of chronic pain [6] . TNF-a, IL-6, and IL-1 have also been shown to indirectly stimulate nociceptors (pain receptors) after nerve degeneration [7] [8] [9] . Preclinical studies have also shown that inhibitors or blockers of TNF-a and IL-1 reduced pain hypersensitivity in animal models of chronic pain [10,11]. More importantly, clinical studies have shown that inflammatory cytokines, particularly IL-6, are associated with symptom burden (including fatigue and pain) induced by radiotherapy in patients with lung cancer [12] or by chemoradiation therapy in patients with colorectal or esophageal cancer [13] . There is relatively very little information about involvement of cytokines/chemokines in the pathophysiology of CINP. However, one clinical study showed that paclitaxel caused increased levels of IL-10, IL-8, and IL-6 in breast cancer patients with flu-like symptoms including joint pain [14] .
In the present retrospective study, we hypothesized that treatment of prostate cancer patients with chemotherapy would result in overexpression of certain inflammatory cytokines during chemotherapy, which in turn would lead to pain in those patients. To examine this hypothesis, we 1) compared, using sing Luminex assay, plasma levels of various cytokines and chemokines in healthy individuals (controls), untreated patients with nonmetastatic prostate cancer, and patients with metastatic prostate cancer after chemotherapy and 2) examined whether plasma levels of those cytokines/ chemokines in patients who received chemotherapy are associated with their pain intensity assessed using numeric rating scale (NRS) pain scores.
Methods

Subjects
A total of 78 Saudi males were enrolled in this study and were divided into four groups: 1) the control group (N ¼ 19), which consisted of normal healthy individuals who are blood bank donors (volunteers) at King Khalid University Hospital, Saudi Arabia, 2) the untreated group (N ¼ 29), which consisted of patients with nonmetastatic prostate cancer who did not receive anticancer treatment (chemotherapy) but had surgery (robotic prostatectomy), 3) the chemotherapy group with pain (N ¼ 20), which consised of patients with metastatic prostate cancer who received three or more cycles of chemotherapy and reported somatic pain, and 4) the chemotherapy group with no pain (N ¼ 10), which consised of patients with metastatic prostate cancer who received three or more cycles of chemotherapy but reported no pain. The untreated cancer patients enrolled in this study were included regardless of their Gleason Score grade. However, all the chemotherapy-treated patients had advanced (metastatic) prostate cancer and were treated with the same chemotherapeutic agent, Docetaxel/ Taxotere (75 mg/m 2 ), which is used for treatment of various types of cancer including breast cancer, lung cancer, head and neck cancer, and prostate cancer. Docetaxel was given intravenously once every three weeks for at least three cycles. As docetaxel is known to cause an allergic reaction, all patients were given steroid tablets (Prednisone, 5 mg) at 12 hours, three hours, and one hour before treatment to prevent such reaction.
Patients with medical conditions that may result in alterations in cytokine levels were excluded, including patients with the following conditions: active infection, rheumatoid arthritis, chronic osteoarthritis, chronic liver disease, renal failure, diabetes mellitus, and chronic low back pain. Patients receiving radiotherapy, hormones, anti-inflammatories, corticosteroids (for any reason other than premedication for chemotherapy), or who were on immune-suppressive medications were also excluded. This study was reviewed and approved by the Institutional Review Board (IRB) of the College of Medicine, King Saud University (IRB approval number E-16-1787), and written informed consent was obtained from all participants.
Cytokines and Chemotherapy-induced Pain
Cytokine Analysis
Blood samples (10 mL) were obtained one day before surgery from each untreated cancer patient (the untreated cancer group), or four weeks after the last dose of chemotherapy from cancer patients treated with chemotherapy (the chemotherapy group with pain and the chemotherapy group with no pain). The blood samples collected from these patients and from healthy subjects were placed in ethylenediamineteraacetic acid (EDTA) tubes and centrifuged at 2500 rpm for 15 minutes. Plasma was aliquoted and stored at -80 C. A panel of 27 plasma cytokines (IL-1a, IL-1b, IL-1, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, FGF, G-CSF, GM-CSF, IFN-c, IP-10, MCP-1, CCL3, PDFG-bb, CCL4, RANTES, TNF-a, VEGF, and IL-17) was quantified for each 50 mL of plasma sample using Luminex assay (Bio-Rad) in duplicate following the manufacturer instructions, as described previously [15] .
Pain Analysis
Prostate cancer patients who received chemotherapy were asked, four weeks after the last treatment cycle, to rate their pain intensity on an 11-point numeric rating scale (NRS), using 0 (no pain) to 10 (worst imaginable pain) (see [16] ). The chemotherapy-treated patients were then divided into two groups according to their NRS: 1) patients with pain (NRS 3) and 2) patients with no pain (NRS ¼ 0). It should be pointed out that no attempt was made to determine the pain type (nociceptive, neuropathic, or mixed) in the cohort of patients included in the present study.
Statistics and Data Analysis
The data in Figure 1 are presented as mean 6 SEM, and statistical analysis was made with one-way repeated-measures analysis of variance (ANOVA). Bonferroni multiple comparisons were made to compare the levels of all the cytokines examined. However, data in Figures 2 to 4 were not normally distributed (ShapiroWilk normality test) and were, therefore, presented as median. Statistical analysis for the data shown in Figures 2 to 4 was conducted using the Kruskal-Wallis test (nonparametric test) followed by Dunn's multiple comparison between all groups. In addition, linear regression analysis was also performed to determine whether the levels of cytokines are correlated with pain intensity ( Figure 5 ). All tests were performed with GraphPad Prism software, version 5 (GraphPad, San Diego, CA, USA), and were two-tailed. P values of less than 0.05 were considered significant (statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001).
Results
Sample
A total of 78 males were enrolled in this study. These were divided into four groups: 1) healthy controls (the control group, N ¼ 19), 2) untreated patients with nonmetastatic prostate cancer (the untreated group, N ¼ 29), 3) patients with metastatic prostate cancer who received chemotherapy and reported pain (NRS 3, N ¼ 20), and 4) chemotherapy-treated patients with no pain (NRS ¼ 0, N ¼ 10). All the patients in the cancer/no chemo group had nonmetastatic prostate cancer and were, therefore, not treated with chemotherapy. Most of the untreated cancer patients (group 2) had no somatic pain or NRS scores of 3 or lower, and only two had visceral pain and one had knee pain. Similarly, almost all of the chemotherapy group (groups 3 and 4) had no somatic pain or NRS scores of 3 or lower before chemotherapy, with only one patient with knee pain. In other words, almost all the patients who were treated with
10 100 1000 * * * * * Plasma cytokines, pg/mL were significantly higher than those of other interleukines (P < 0.001 for IL-1a; P < 0.01 for IL-17). The level of IL1a was also significantly higher than that of IL-17 (P < 0.001). B) Plasma concentrations of other cytokines and chemokines showing that the mean concentration of RANTES was significantly higher than that of other cytokines and chemokines (P < 0.001).
chemotherapy had no preexisting pain prior to chemotherapy. Thus it is likely that the pain reported by prostate cancer patients after chemotherapy is chemotherapy-induced and not cancer pain.
The sample characteristics are shown in Table 1 . All the groups were Saudi males, and all the untreated cancer patients and chemotherapy-treated patients had surgical tumor resection. It should be pointed out that the untreated cancer patients were enrolled in this study regardless of their Gleason Score grade, whereas all the chemotherapy-treated patients had advanced (metastatic) prostate cancer. The most common comorbidity among the patients was hypertension. As shown in the patients' demographic table (Table 1) , there were no significant differences in the mean age or the mean body index (BMI) between the four groups.
Inflammatory Cytokines in the Plasma of Healthy Controls (Control Group)
The distribution of plasma concentrations (in pg/mL) of all the 27 cytokines examined in healthy controls (group 1) is shown in Figure 1 . Figure 1A shows that, of the 14 interleukins examined, the mean levels of IL-1a and IL-17 were significantly higher than those of other interleukins (P < 0.001 for IL-1a; P < 0.01 for IL-17). The mean level of IL-1a was also significantly higher than that of IL-17 (P < 0.001). Figure 1B shows that, of the remaining cytokines, RANTES was the only cytokine whose mean plasma concentration was significantly higher than that of other cytokines and chemokines (P < 0.001).
Inflammatory Cytokines in the Plasma of Untreated Prostate Cancer Patients
All cancer patients (group 2) had measurable levels of all the assessed 27 cytokines at baseline (before surgery). Multiple comparisons (using the Kruskal-Wallis test followed by Dunn's multiple comparison between all groups) of the cytokines levels between all the four groups showed that the median concentrations of IL1a, GM-CSF, RANTES, and IFN-c were significantly lower (P < 0.05 for all) in the untreated cancer group than the control group (data not shown).
Changes in Cytokine Levels in Prostate Cancer Patients in Response to Chemotherapy
As shown in Figures 2 and 3 , out of the 27 cytokines examined, the median levels of five cytokines were significantly increased in the chemotherapy-treated patients with pain (group 3), compared with the untreated cancer patients (group 2). These cytokines are IL-6 (P < 0.01), IL-8 (P < 0.01), VEGF (P < 0.01), Eotaxin (P < 0.05), and IP-10 (P < 0.01). As shown in Figures 2 and 3 , of those five cytokines, the median levels of four cytokines (IL-6, IL-8, VEGF, and IP-10) were also significantly higher in group 3 (the chemotherapy-treated patients with pain) than group 4 (the chemotherapy-treated patients with no pain).
As shown in Figure 4 , the plasma levels of three other cytokines/chemokines (IL-15, CCL4, and RANTES) were also higher in the chemotherapy-treated patients with pain (group 3) than in the untreated cancer patients (group 2), but the change did not reach statistical significance (P > 0.05). However, the levels of those three cytokines were significantly higher in group 3 (chemotherapytreated patients with pain) than group 4 (chemotherapytreated patients without pain) (Figure 4) . Unexpectedly, plasma levels of RANTES were significantly (P < 0.05) lower in the untreated cancer group than the healthy control group (Figure 4) . These elevated RANTES levels in the control group may be due to some kind of inflammatory conditions in some of the healthy subjects.
Correlation Between Cytokine Levels and Pain Intensity in the Chemotherapy-Treated Patients with Pain
To determine whether the levels of cytokines that increased significantly in the chemotherapy-treated There were no significant differences in the mean age or the mean body mass index (mean 6 SEM) between the different groups (analysis of variance). The question mark indicates that information is unavailable.
patients with pain (group 3) are correlated with the pain intensity in this cohort of patients, linear regression analysis was performed. Only patients with complete paired data for both variables/types of measurements (cytokines and pain scores) were included in this analysis. Of the 27 cytokines examined, only the increase in the IL-6 levels was correlated positively and significantly with pain intensity (P < 0.05, R 2 ¼ 0.28) (see Figure 5 ).
Discussion
The present study was aimed at examining our hypothesis that the cumulative dose of chemotherapy in prostate cancer patients would result in overexpression of certain pro-inflammatory cytokines during chemotherapy, which in turn would lead to pain in those patients. Consistent with this hypothesis, we found that chemotherapy-treated prostate cancer patients with pain (NRS 3) exhibited significantly increased levels of several pro-inflammatory cytokines, particularly IL-6, which was the only cytokine (out of the 27 cytokines examined) that was positively and significantly correlated with pain intensity in the chemotherapy-treated patients with pain. These findings suggest that the cytokines (IL-6, IL-8, Eotaxin, VEGF, and IP-10) that exhibited significant increases, particularly IL-6, are involved in the pathophysiology of chemotherapy-induced pain.
A few previous studies have evaluated changes in the levels of cytokines in cancer patients after radiotherapy, chemotherapy, or chemoradiation therapy. Two such studies have shown that inflammatory cytokines, including IL-6, are associated with the so-called symptom burden (including fatigue and pain) induced by radiotherapy in patients with lung cancer [12] or by chemoradiation therapy in patients with colorectal or esophageal cancer [13] . A clinical study showed that paclitaxel caused increased levels of IL-10, IL-8, and IL-6 in breast cancer patients with flu-like symptoms including joint pain [14] . It has also been shown that IL-6 levels in the plasma of adult patients with advanced and , and VEGF (C) in the chemotherapy-treated patients with pain (CT-pain, group 3, third column) are significantly higher than those of untreated cancer patients (Cancer, group 2, second column) and the chemotherapy-treated patients without pain (CT-no pain, group 4, fourth column). The statistical analysis of multiple comparisons (comparing all the four groups) was performed using the Kruskal-Wallis test (nonparametric test) followed by Dunn's multiple comparison between all groups, and the level of significance is indicated with asterisks above the third and fourth columns (*P < 0.05; **P < 0.01).
refractory malignancies increased slightly in response to chemotherapy (flavopiridol) [17] and that the small increase in IL-6 levels could lead, in those patients, to a chemotherapy-induced pro-inflammatory syndrome consisting of fever, fatigue, and "local" tumor pain [17] . Other studies have evaluated IL-6 levels in prostate cancer patients before and after chemotherapy treatment [18] [19] [20] , but none of these or the aforementioned studies have assessed pain in their cohorts of patients. Thus, our current study is, to the best of our knowledge, the first study to show that levels of certain cytokines, particularly IL-6, are associated with pain intensity in prostate cancer patients who received chemotherapy. Interestingly, however, our findings are consistent with those of a study [21] that found that women who developed symptoms of CIPN after chemotherapy treatment for their breast cancer had significantly higher levels of IL-6 compared with chemotherapy-treated women with breast cancer without CIPN symptoms. Taken together, these findings suggest that IL-6 may be important in the pathophysiology of CIPN. Several studies have reported that certain cytokines were associated with pain in other types of neuropathic pain (NP) conditions including NP associated with low back pain, nerve compression due to a herniated disc, and spinal cord injuries [22] [23] [24] Although the NRS method used to assess pain intensity in the present study is subjective, it is one of the most common pain rating scales used in clinical research settings. It is a valid, reliable, and appropriate method of assessing pain intensity and has good sensitivity [16] . The NRS of 3 or higher used in the present study was chosen based on previous studies that showed that, in cancer patients, the cutoff point between mild and moderate pain ranged from 1 to 4 (average ¼ 3.5 6 1.08) and that the cutoff point between moderate and severe pain ranged from 4 to 7 (average¼ 6.2 6 0.92) (see [25] for a review). The underlying type of pain in our cohort of patients could not be determined because the reported pain was not classified into subgroups of nociceptive, neuropathic, or mixed pain. However, it is likely to be neuropathic because it well established that 10% to 100% of cancer patients receiving chemotherapy report NP symptoms (see the Introduction section), depending upon the particular anticancer drug(s) used, the dosing regimen, treatment duration, and preexisting neuropathy of other origin, such as diabetes [2] . IL-6 is a powerful pro-inflammatory cytokine that is produced in response to injury of the peripheral nerves, and it is involved in the recruitment of other cytokines, promoting infiltration of T cells, and maintaining pain sensation [26] [27] [28] . In addition, IL-6 has been shown to affect prostate cancer cell proliferation, apoptosis, differentiation, and therapy resistance [29] . One of the studies that examined IL-6 levels in prostate cancer patients reported that high levels of baseline IL-6 were associated with poor response to chemotherapy (taxane) treatment and that the transition point between high and low IL-6 levels was 16 pg/mL [18] . However, it was found in another study [19] that only one of the patients had a baseline IL-6 level higher than 16 pg/mL and that IL-6 levels decreased by 35% in prostate cancer responders to chemotherapy but increased by 76% in nonresponders. IL-6 levels were found in a more recent study [20] to be more than 250-fold higher in prostate cancer patients after chemotherapy and that patients with an IL-6 greater than 12.5 pg/mL had worse survival than those with levels lower than 12.5 pg/mL. In addition to these clinical studies that provided evidence for involvement of cytokines in the side effects of chemotherapy, there is also ample evidence from preclinical (animal) studies implicating certain inflammatory cytokines such as IL-1b, IL-6, and TNF-a in the process of pathological pain including CINP [30] [31] [32] . For example, paclitaxel has been shown to induce NP behavior by increasing the levels of TNF-a, and IL-1b in the lumbar dorsal root ganglia [30] . Blocking the synthesis and/ or release of pro-inflammatory cytokines with minocycline and thalidomide has also been shown to reduce NP behavior in the paclitaxel model of CINP [31] . IL-6 has also been shown to play a central role in the neuronal reaction to nerve injury and in the development of nerve injury-induced NP behavior in rodents (see [32] ). The findings of studies using IL-6 knockout mice suggest that IL-6 exerts its effect on pain behavior indirectly through sympathetic sprouting in the dorsal root ganglia [33] and that IL-6 is involved in the activation of glial cells and in the regulation of the expression of neuronal neuropeptides [34] . Pain scores IL-6, pg/mL Figure 5 Correlation between plasma concentrations of IL-6 and self-reported pain in the chemotherapytreated patients. The figure shows the relationship of subjective pain scores to the plasma concentration of IL-6 in the chemotherapy-treated patients with pain. The x-axis shows the subjective pain scores on an 11-point numeric rating scale (NRS) with the NRS ranging from 3 to 8, whereas the y-axis shows the plasma concentration (pg/mL) of IL-6. Note that there is a significant positive correlation (P ¼ 0.024) between pain scores and levels of plasma levels of IL-6, albeit with high variability, leading to a low R 2 value of 0.28 (shown with P values on top of the graph).
the median plasma levels of IL-15 (A), CCL4 (B), and RANTES (C) in the chemotherapy-treated patients with pain (CT-pain, group 3, third column) are significantly higher than those of the chemotherapy-treated patients without pain (CT-no pain, group 4, fourth column). Note that the median plasma level of RANTES in the cancer group is significantly lower (P < 0.05) than that of the control group. For details, see the legend to Figure 2 .
It should be pointed out that it is possible that even the cytokines that did not exhibit a significant change in the plasma levels of patients may contribute to chemotherapy-induced side effects because those cytokines might have been turned over more rapidly or exhibited a transient change before the plasma sample was drawn. The underlying molecular and cellular neuronal mechanisms of CINP are incompletely understood but are believed to be diverse and complex and to include changes in ion channels, neurotransmitters, and their receptors, as well as other functional changes in neurons and glia (for a review, see [1] ).
It is noteworthy that the present retrospective study had several limitations that should be pointed out. The most notable limitation being the small sample size, especially that of the chemotherapy-treated group with pain (N ¼ 10). Another shortcoming of this study is the lack of cytokines data before chemotherapy for the chemotherapy-treated patients (due to unavailability of blood samples). Given that IL-6 levels are elevated in prostate cancer patients after prostatectomy [35] , availability of such data would have clarified whether the elevated IL-6 levels in the chemotherapy-treated patients are due mainly to chemotherapy or to cancer. Nevertheless, since IL-6 levels are more than 250-fold higher in prostate cancer patients after chemotherapy [20] , and since our findings show that IL-6 levels are significantly higher in the chemotherapy-with pain group than both the cancer group with no chemotherapy and the subgroup of chemotherapy-with no pain group (the main comparison group), our results suggest that the pain reported by patients treated with chemotherapy is more likely to be induced by chemotherapy and not by other factors.
In conclusion, our findings suggest that the proinflammatory cytokines IL-6 and IL-8, the chemokines Eotaxin, VEGF, and IP-10, and particularly IL-6, may be involved in the pathophysiology of CINP. However, our results are descriptive and cannot, therefore, shed light on the precise underlying mechanisms of CINP or on the cause-and-effect relationship between chemotherapy-induced changes in plasma cytokine levels and CINP. Thus, further mechanistic studies are warranted to clarify these points and to determine whether or not IL-6 levels rise in a dose-response relationship. The findings provide further support to the notion that cytokines play a key role in pathological pain and suggest that these cytokines, and particularly IL-6, might be potential new targets for pain control in cancer patients receiving chemotherapy.
